LY2109761_LCMS_05432_MedChemExpress

合集下载

Gelucire-14-44-SDS-MedChemExpress

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Nov.-23-2018Print Date:Nov.-23-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Gelucire 14/44Catalog No. :HY-Y1892CAS No. :121548-04-71.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:N/AMolecular Weight:N/ACAS No. :121548-04-74. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Pure form-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Oil)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

EL-102_SDS_MedChemExpress

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :EL-102Catalog No. :HY-16187CAS No. :1233948-61-21.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:EL 102; EL102Formula:C19H16N2O3S2Molecular Weight:384.47CAS No. :1233948-61-24. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

茶多酚对人脂肪来源间充质干细胞成骨分化的影响

茶多酚对人脂肪来源间充质干细胞成骨分化的影响王华1，齐玉成-杨云芳-赵艺洋2,王慧1，陈培1，杨旭芳1(1.牡丹江医学院，黑龙江牡丹江157011；2.南方医科大学第一临床医学院，广东广州510515)摘要：目的探讨茶多酚(Epigallocatechin-3-gallate,EGCG)对人脂肪间充质干细胞(human adipose-derived mesenchy^-mal stem cells,hADSCs)成骨分化的影响。

方法利用胶原酶消化法和贴壁筛选法从人脂肪组织中分离、培养及扩增hADSCs,倒置显微镜下观察各代hADSCs的形态学特点;利用流式细胞术检测各代hADSCs免疫学表型;取P3代细胞进行成骨诱导分化，实验分三组，即未诱导组、常规成骨诱导组与EGCG组(常规成骨诱导+5^mol/L EGCG),14d后，镜下观察细胞形态学改变及碱性磷酸酶(ALP)染色。

结果体外分离、培养的hADSCs形态均一;流式细胞术结果显示hADSCs具备间充质干细胞的免疫学表型，即CD44、CD73、CD105阳性;成骨诱导14d后部分细胞由长梭形变成多角形，细胞呈现聚集趋势；ALP染色显示EGCG组呈强阳性。

结论成功的从脂肪组织中分离培养出了hADSCs,EGCG能加强其成骨分化能力，这将为骨质疏松症的临床药物开发提供新的思路，亦为组织工程骨的构建提供丰富可靠的种子细胞来源。

关键词：EGCG；人脂肪来源间充质干细胞;成骨分化中图分类号：R595.2文献标识码：A文章编号：1001-7550(2021)01-0001-04Effect of EGCG on osteogenic differentiation of human adipose-derived mesenchymal stem cellsWANG Hua et al(Mudanjiang Medical University,Mudanjiang157011,China)Abstract:Objective To explore the effect of tea polyphenol EGCG on the osteogenic differentiation of human adipose-derived mesenchymal stem cells(hADSCs) .Methods To isolate,culture and amplify hADSCs from human adipose tissue by collagenase digestion and adherent screening methods, the morphological characteristics of each passage of hADSCs were observed under an inverted microscope.The immunophenotype of each generation of hADSCs was detected by flow-cytometry.P3passage cells were taken for osteogenic induction and differentiation,and were divided into three groups:non-induced group, conventional osteogenic induction group and EGCG group(conventional osteogenic induction with+5Rmol/L EGCG).After14days,morphological changes and alkaline phosphatase(ALP)staining were observed under the microscope.Results The morphology of hADSCs isolated and cultured in vitro was uni-form.The results of flow cytometry showed that hADSCs had the immunophenotype of mesenchymal stem cells,such as CD44,CD73and CD105.After14days of osteogenic induction,some cells changed from long spindle shape to polygonal shape,and the cells showed aggregation trend.ALP staining showed strong positive in EGCG group.Conclusion hADSCs have been successfully isolated and cultured from adipose tissue.EGCG can enhance the osteogenic differentiation ability of hADSCs,which will provide a new idea for the clinical drug development of osteoporosis and provide an abundant and reliable source of seed cells for the construction of tissue-engineered bone.Key words:EGCG;human adipose-derived mesenchymal stem cells；osteogenic differentiation随着人口老龄化,骨质疏松症已成为影响人们生活质量的主要因素之一⑷。

基于LC-MS

分析检测基于LC-MS/MS的蔬菜农药残留基质效应分析单晓丽1，周峰1，李东1，王国洋2（1.安丘市检验检测中心有限公司，山东潍坊 262100；2.山东柠檬生化有限公司，山东潍坊 262100）摘要：为明确蔬菜农药残留对于基质效应的影响，本文选取韭菜、芹菜、茄子3种蔬菜，利用液相色谱-串联质谱法对蔬菜中6种农药残留进行测定，通过基质和溶剂标准曲线的斜率，判定其基质效应。

试验结果表明，不同蔬菜中农药残留量的基质效应主要为信号抑制作用。

因此，在后期农药检测中，可通过使用基质标准曲线进行定量测定，从而提高检测结果的准确性，对于保障食品安全具有重要意义。

关键词：LC-MS/MS；蔬菜农药残留；基质效应Matrix Effect Analysis of Vegetable Pesticide Residues Basedon LC-MS/MSSHAN Xiaoli1, ZHOU Feng1, LI Dong1, WANG Guoyang2(1.Anqiu Inspection and Testing Center Co., Ltd., Weifang 262100, China;2.TTCA Co., Ltd., Weifang 262100, China)Abstract: In order to clarify the inf luence of pesticide residues in vegetables on the matrix effect, three kinds of vegetables, leek, celery and eggplant, were selected in this paper. The six pesticide residues in vegetables were determined by liquid chromatography-tandem mass spectrometry. The matrix effect was determined by the slope of the matrix and solvent standard curve. The results showed that the matrix effect of pesticide residues in different vegetables was mainly signal inhibition. Therefore, in the later pesticide detection, the matrix standard curve can be used for quantitative determination, so as to improve the accuracy of the test results, which is of great significance for ensuring food safety.Keywords: LC-MS/MS; vegetable pesticide residues; matrix effect随着蔬菜农药残留问题的日益突出，农药残留检测已成为当前食品安全研究领域的重点内容。

龙须菜降压肽提取物和龙须菜降压肽及其应用[发明专利]

(19)中华人民共和国国家知识产权局(12)发明专利申请(10)申请公布号 (43)申请公布日 (21)申请号 201810819628.2(22)申请日 2018.07.24(71)申请人中国科学院海洋研究所地址 266071 山东省青岛市市南区南海路7号(72)发明人张全斌　邓真真　刘英娟　王晶　耿丽华　岳洋　(74)专利代理机构沈阳科苑专利商标代理有限公司 21002代理人马驰(51)Int.Cl.C07K 7/06(2006.01)C12P 21/06(2006.01)C07K 1/14(2006.01)A61K 38/08(2006.01)A61P 9/12(2006.01)A23L 33/18(2016.01)(54)发明名称龙须菜降压肽提取物和龙须菜降压肽及其应用(57)摘要本发明公开了龙须菜降压肽及其在制备降血压药物和保健食品中的应用。

龙须菜降压提取物经酶解获得，对该提取物进一步分离纯化得到一特定序列的多肽，该降压肽的氨基酸序列为Phe -Gln -Ile -Asn -[Met(O)]-Cys -Ile -Leu -Arg (F Q I N[M(O )]C I L R )，质谱鉴定分子量为1153.43Da。

本发明筛选的龙须菜降压肽具有显著的血管紧张素转化酶抑制活性。

在体外表现为温度、pH、模拟胃肠消化和血管紧张素转化酶(ACE)降解稳定性。

酶动力学考察显示该多肽为一种ACE的非竞争性抑制剂。

在体外和非自发性高血压大鼠(SHRs )体内都显示出良好的降压效果，可用于高血压治疗相关的保健品和药品。

权利要求书1页说明书6页附图3页CN 108892710 A 2018.11.27C N 108892710A1.一种龙须菜降压肽，其特征在于:所述龙须菜降压肽具有下述序列中的一种或二种以上，第一序列：具有序列表SEQ ID NO：1中氨基酸序列,多肽序列为Phe -Gln -Ile -Asn -Met -Cys -Ile -Leu -Arg(FQINMCILR)；第二序列：Phe -Gln -Ile -Asn -Met -Cys -Ile -Leu -Arg(FQINMCILR)的甲硫氨酸修饰为甲硫氨酸亚砜的多肽序列；第三序列：Phe -Gln -Ile -Asn -Met -Cys -Ile -Leu -Arg(FQINMCILR)的半胱氨酸修饰为半胱氨酸亚砜的多肽序列；第四序列：Phe -Gln -Ile -Asn -Met -Cys -Ile -Leu -Arg(FQINMCILR)的甲硫氨酸和半胱氨酸修饰为甲硫氨酸亚砜和半胱氨酸亚砜的多肽序列。

LCMS检测西他沙星原料中基因毒性杂质的含量

LC-MS检测西他沙星原料中基因毒性杂质的含量石莹1宋雪洁3李浩冬2路显锋2*1药物研究院分析所，扬子江药业集团，泰州2253212药物制剂新技术国家重点实验室，扬子江药业集团，泰州2253213质量管理部，扬子江药业集团，泰州225321摘要建立了LC-MS 法测定西他沙星中基因毒性杂质对甲苯磺酸甲酯和对甲苯磺酸乙酯含量的方法。

方法:采用Agilent Poroshell 120 EC-C18色谱柱；流动相为纯水（0.1%甲酸）:甲醇（V/V）=60:40；稀释剂为乙腈（0.1%甲酸）:纯水（V/V）=50:10；柱温为40℃；进样体积为5µl；流速为0.4ml/min；采用正离子模式进行扫描。

对甲苯磺酸甲酯测定浓度在0.76ng/ml~15.27ng/ml范围内，线性关系良好；对甲苯磺酸乙酯测定浓度在0.75ng/ml~15.01ng/ml范围内，线性关系良好。

对甲苯磺酸甲酯的定量限为0.0038ng；对甲苯磺酸乙酯的定量限为0.0038ng。

杂质回收率在限度浓度80%、100%和160%三个浓度水平均在90~110%之间，该方法准确度良好。

该方法适用于西他沙星原料中对甲苯磺酸甲酯和对甲苯磺酸乙酯的检测。

西他沙星(sitafloxacin)是日本第一制药有限公司继左氧氟沙星后开发出的一种强力广谱新氟喹诺酮类抗菌剂，该药对革兰氏阳性球菌，革兰氏阴性菌以及厌氧菌的抗菌活性是左氧氟沙星的4～32倍，同时对肺炎球菌DNA 促旋酶和拓扑同功酶有双重抑制作用。

临床表现有极广的抗菌谱，特别是对呼吸道的病菌有极强的抗菌活性。

因西他沙星的一个起始物料为对甲苯磺酸盐，在后续反应中对甲苯磺酸若有残留，可能会与溶剂甲醇、乙醇反应生成具有基因毒性的杂质—对甲苯磺酸甲酯和对甲苯磺酸乙酯，故采用LC-MS法对产品中的对甲苯磺酸甲酯/乙酯进行控制。

1、实验部分1.1仪器与试药Agilent 1200液相色谱仪(美国安捷伦公司)；Agilent 6460三重串联四极杆质谱仪(美国安捷伦公司)；XP205型电子天平(瑞士梅特勒托利多公司)。

Thiamet_G_LCMS_16482_MedChemExpress

=====================================================================Acq. Operator : Li Shan(LCMS-02) Seq. Line : 84Acq. Instrument : HY-LCMS-02 Location : P2-C-05Injection Date : 6/5/2015 4:13:47 PM Inj : 1 Inj Volume : 3.000 µl Acq. Method : D:\AGLIENT 1260\DATA\20150605\20150605 2015-06-05 09-21-31\100-1000MS+3MIN- 1.5_(0.02%FA).M Last changed : 6/5/2015 9:21:31 AM by Li Shan(LCMS-02)Analysis Method : D:\AGLIENT 1260\METHOD\5-80A(RP-HPLC).M Last changed : 6/5/2015 4:55:55 PM by Li Shan(LCMS-02) (modified after loading)Method Info : 10-80A,16MIN Catalog No : HY-12588 Batch#16482 A-RP-132 Additional Info : Peak(s) manually integrated min0.51 1.52 2.53mAU200400600800DAD1 B, Sig=214,4 Ref=off (D:\AGLIENT...60\DATA\20150605\20150605 2015-06-05 09-21-31\BIZ2015-605-DJL9.D)0.394 0.498 2.228 ===================================================================== Area Percent Report ===================================================================== Sorted By : Signal Multiplier : 1.0000Dilution : 1.0000Do not use Multiplier & Dilution Factor with ISTDs Signal 1: DAD1 B, Sig=214,4 Ref=off Peak RetTime Type Width Area Height Area # [min] [min] [mAU*s] [mAU] %----|-------|----|-------|----------|----------|--------| 1 0.394 MM 0.0425 2829.96558 1108.66125 99.2783 2 0.498 MM 0.0339 5.77030 2.83656 0.2024 3 2.228 MM 0.0639 14.80108 3.85942 0.5192 Totals : 2850.53696 1115.35724 ===================================================================== *** End of Report ***=====================================================================Acq. Operator : Li Shan(LCMS-02) Seq. Line : 84Acq. Instrument : HY-LCMS-02 Location : P2-C-05Injection Date : 6/5/2015 4:13:47 PM Inj : 1 Inj Volume : 3.000 µl Acq. Method : D:\AGLIENT 1260\DATA\20150605\20150605 2015-06-05 09-21-31\100-1000MS+3MIN- 1.5_(0.02%FA).M Last changed : 6/5/2015 9:21:31 AM by Li Shan(LCMS-02)Analysis Method : D:\AGLIENT 1260\METHOD\5-80A(RP-HPLC).M Last changed : 6/5/2015 4:56:55 PM by Li Shan(LCMS-02) (modified after loading)Method Info : 10-80A,16MIN Catalog No : HY-12588 Batch#16482 A-RP-132 Additional Info : Peak(s) manually integrated min0.51 1.52 2.530100000200000300000400000500000MSD1 TIC, MS File (D:\AGLIENT 1260\DATA\20150605\20150605 2015-06-05 09-21-31\BIZ2015-605-DJL9.D) ES-API, Pos, Sca0.392MS Signal: MSD1 TIC, MS File, ES-API, Pos, Scan, Frag: 50 Spectra averaged over upper half of peaks. Noise Cutoff: 1000 counts. Reportable Ion Abundance: > 10%. Retention Mol. Weight Time (MS) MS Area or Ion 0.392 2110102 250.10 I 249.10 Im/z 100200300400500600020406080100*MSD1 SPC, time=0.377:0.413 of D:\AGLIENT 1260\DATA\20150605\20150605 2015-06-05 09-21-31\BIZ2015-605-DJL9.D ES-API,Max: 377429251.1 249.1 *** End of Report ***。

内皮细胞提取和高效液相色谱－电喷雾飞行时间质谱联用预测玄参中的活性成分

内皮细胞提取和高效液相色谱－电喷雾飞行时间质谱联用预测玄参中的活性成分祝艳斐;毕志明;刘承伟;任美婷;吴斐华;李萍【期刊名称】《中国药科大学学报》【年(卷),期】2008(39)3【摘要】目的:应用内皮细胞提取和高效液相色谱-电喷雾飞行时间质谱联用(HPLC-ESI/TOF MS)预测玄参的活性成分。

方法:应用内皮细胞作为靶细胞,中药提取液中的活性成分可选择性地与其结合,洗去未结合的成分,用HPLC-ESI/TOF MS 对细胞解离液中的成分进行分析。

结果:从玄参提取液中检测出6个可与内皮细胞结合的成分,其中3个鉴定为安格洛苷C(angoroside C)、肉桂酸(cinnamic acid)和哈巴俄苷(harpagoside)。

结论:细胞解离液中检测到的成分为玄参中与内皮细胞有结合作用的成分,本方法可用于预测中药中与内皮细胞相结合的活性成分。

【总页数】4页(P228-231)【关键词】内皮细胞提取;高效液相色谱-电喷雾飞行时间质谱联用法;玄参;活性成分【作者】祝艳斐;毕志明;刘承伟;任美婷;吴斐华;李萍【作者单位】中国药科大学生药学教研室;中国药科大学现代中药教育部重点实验室【正文语种】中文【中图分类】O657.63【相关文献】1.高效液相色谱与电喷雾飞行时间质谱联用鉴定胰岛素注射液 [J], 刘劼;陈军辉;王小如;黎先春2.靶细胞提取和高效液相飞行时间质谱联用分析预测丹参中的活性成分 [J], 董倩倩;李萍;宋越;毕志明3.紫草中萘醌类化学成分的快速高效液相色谱-飞行时间质谱联用技术分析 [J], 毛艳;张瑞萍;贺金华;贺玖明;蔡晓翠;严欢;康雨彤4.高效液相色谱/电喷雾-离子阱-飞行时间质谱联用法分析桂枝汤的化学成分 [J], 袁鹏飞;张雯;徐风;刘广学;尚明英;蔡少青5.高效液相色谱-高分辨飞行时间质谱联用技术筛选中国和俄罗斯人参中的差异成分 [J], 葛丽蕊;陈紫烨;胡婷婷;张勋;马书民;宋清莲;李志远;李燕鹭;赵韫慧;刘少桐;刘鹏因版权原因，仅展示原文概要，查看原文内容请购买。

α-酮戊二酸依赖型酶的酶活检测试剂盒及其应用[发明专利]

(19)中华人民共和国国家知识产权局(12)发明专利申请(10)申请公布号 (43)申请公布日 (21)申请号 201711346017.2(22)申请日 2017.12.15(71)申请人上海交通大学医学院地址 200025 上海市黄浦区重庆南路227号(72)发明人张良　罗静　张会冰　孟周文理　(74)专利代理机构上海翼胜专利商标事务所(普通合伙) 31218代理人翟羽(51)Int.Cl.C12Q 1/32(2006.01)C12Q 1/26(2006.01)(54)发明名称α-酮戊二酸依赖型酶的酶活检测试剂盒及其应用(57)摘要本发明公开α-酮戊二酸依赖型酶的酶活检测试剂盒及其应用，所述试剂盒包括还原型辅酶Ⅱ(NADPH)或者还原型辅酶Ⅰ(NADH)中的一种，异柠檬酸脱氢酶IDH突变体蛋白和缓冲盐，所述IDH突变体蛋白是指IDH特定氨基酸突变后所获得的具有催化α-酮戊二酸(2-OG )新功能的IDH突变体蛋白。

作为一个优选方案，所述试剂盒还包括竞争亚铁离子的金属离子。

本发明提供了一种高效率高精确度检测α-酮戊二酸含量的方法，可用于检测α-酮戊二酸依赖型酶的酶催化活性，测定其酶动力学参数，及针对该类型酶展开高通量药物筛选。

该方法解决了α-酮戊二酸依赖型酶的酶活检测操作繁琐，准确度和可重复性差，通量低，难以进行高通量药物筛选等诸多问题。

权利要求书2页说明书9页附图5页CN 109929908 A 2019.06.25C N 109929908A1.α-酮戊二酸依赖型酶的酶活检测试剂盒，其特征在于，所述试剂盒包括还原型辅酶Ⅱ或者还原型辅酶Ⅰ中的一种，异柠檬酸脱氢酶IDH突变体蛋白和缓冲盐，所述IDH突变体蛋白是指IDH特定氨基酸突变后所获得的具有催化α-酮戊二酸新功能的IDH突变体蛋白。

2.根据权利要求1所述的α-酮戊二酸依赖型酶的酶活检测试剂盒，其特征在于，所述试剂盒还包括竞争亚铁离子的金属离子，所述竞争亚铁离子的金属离子包括锰离子、镁离子、钙离子、钴离子、镍离子、铜离子、锌离子及其同族金属中的一种或几种金属离子。

链激酶基因及其分离与表达[发明专利]

专利名称：链激酶基因及其分离与表达专利类型：发明专利
发明人：周俐梅,王嘉玺,邹民吉
申请号：CN96103367.3
申请日：19960404
公开号：CN1161376A
公开日：
19971008
专利内容由知识产权出版社提供
摘要：本发明涉及生物工程链激酶基因及其分离与表达。

本发明从中国人群中分离得到的化脓性链球菌中提取其染色体DNA，通过聚合酶链式反应(POLYMERASECHAINREACTION)大量扩增得到目的SK基因。

SK基因在大肠杆菌中的表达水平占菌体总蛋白的60％以上，序列同源性比较表明其活性部位十分保守，但在非活性部位V1区(第522-732碱基)和V2区(第810-870碱基)有较大变异。

申请人：北京埃尔法生物医学技术有限公司,北京四环医学技术贸易公司
地址：100850 北京市海淀区太平路27号
国籍：CN
更多信息请下载全文后查看。

异硫氰酸荧光素标记尿激酶的制备与性能研究

异硫氰酸荧光素标记尿激酶的制备与性能研究张雅娟;俞洁;张冬未;梁洪泽;梁明明;赵玲玲【期刊名称】《宁波大学学报（理工版）》【年(卷),期】2016(029)003【摘要】Fluorescein labeled urokinase (FITC-uPA) is synthesized by the reaction of fluorescein isothiocyanate (FITC) with urokinase (uPA), a kind of protein drug for thrombolysis. The reaction is confirmed by1HNMR and FT-IR. The ratio (F/P) of fluorescein over protein is 0.45. The urokinase is found to possess good fluorescent property after fluorescein is labeled, and the detection limit of fluorescence is as low as 10-6 g·mL-1. There is obvious linear relationship between the fluorescein intensity and concentration of FITC-uPA within the concentration range of 1-100μg·mL-1, which can be used for qualitative/quantitative detection and tracking of micro/trace proteins. FITC-uPA has similar hydrodynamic diameter and thrombolysis efficiency with the unlabeled urokinase. Based on the study, it can be concluded that the fluorescein-label is a simple and effective method for thrombolysis drug labeling without affecting the biological active of urokinase.%用异硫氰酸荧光素(FITC)对溶栓蛋白药物尿激酶(uPA)进行了荧光标记，制备了荧光素标记的尿激酶(FITC-uPA)，经核磁谱及红外谱表征证实了反应能有效进行，其荧光素/蛋白值(F/P)值为0.45.尿激酶经荧光素标记后，具有良好的荧光性质，其荧光检测下限低达10-6 g·mL-1.在1~100g·mL-1范围内，荧光强度与溶液浓度具有很好的线性关系，可用于微/痕量蛋白质的定量/定性检测和跟踪标记.荧光素标记后的尿激酶，其流体力学直径与未标记的尿激酶基本一致，其体外溶栓能力也与未标记的尿激酶相当，说明FITC标记基本不影响尿激酶的生物活性，是一种简单、有效的溶栓药物标记方法.【总页数】5页(P78-82)【作者】张雅娟;俞洁;张冬未;梁洪泽;梁明明;赵玲玲【作者单位】宁波大学材料科学与化学工程学院，浙江宁波 315211;宁波大学材料科学与化学工程学院，浙江宁波 315211;宁波大学材料科学与化学工程学院，浙江宁波 315211;宁波大学材料科学与化学工程学院，浙江宁波 315211;马鞍山市人民医院，安徽马鞍山 243000;宁波大学材料科学与化学工程学院，浙江宁波315211【正文语种】中文【中图分类】TQ937【相关文献】1.异硫氰酸荧光素标记壳聚糖的研究 [J], 贺继东;夏文水2.异硫氰酸荧光素标记抗体的固体基质室温磷光性质研究 [J], 刘佳铭;付艳;余冰宾;李隆弟3.大肠杆菌O157∶H7异硫氰酸荧光素标记抗体的制备及评价 [J], 方珍;鞠文;秦亚楠;孟日增;潘风光4.膜联蛋白V的异硫氰酸荧光素标记和应用研究 [J], 蔡炯;李方;牛娜;王世真5.异硫氰酸荧光素标记万古霉素的制备及其与细菌相互作用的荧光检测 [J], 徐蓉;阮林高;戈梅;张怡轩因版权原因，仅展示原文概要，查看原文内容请购买。

季铵盐lcms分子离子峰

季铵盐lcms分子离子峰
季铵盐是一类常见的化合物，具有广泛的应用领域。

尤其是季铵盐的液相色谱-质谱联用技术（LC-MS）分子离子峰，为化学分析提供了强有力的工具。

LC-MS是一种结合了液相色谱和质谱技术的分析方法。

它能够将复杂的混合物分离，并通过质谱仪器进行精确的质量测定。

在这个过程中，季铵盐作为样品中的一种离子化合物，会通过液相色谱柱进行分离，并在质谱仪器中产生相应的质谱信号。

季铵盐的分子离子峰可以提供丰富的信息，用于化学物质的鉴定和定量分析。

通过对分子离子峰的形状、强度和相对丰度的分析，可以确定样品中季铵盐的种类和含量。

这对于药物研发、环境监测和食品安全等领域具有重要意义。

在LC-MS分析中，季铵盐的分子离子峰常常呈现出清晰的峰形和丰富的峰谱。

这使得分析人员能够准确地判断季铵盐的存在和浓度。

同时，通过不同的质谱技术，还可以进一步确定季铵盐的结构和化学性质。

在实际应用中，LC-MS分析季铵盐的分子离子峰需要仔细操作和精确的实验条件。

只有充分理解液相色谱和质谱原理，才能正确解读分析结果。

此外，还需要合理选择分析方法和仪器参数，以确保分析结果的准确性和可重复性。

季铵盐LC-MS分子离子峰是一项重要的化学分析技术。

它不仅可以用于季铵盐的鉴定和定量分析，还可以在其他化学研究领域发挥重要作用。

相信随着技术的进一步发展，季铵盐LC-MS分析将在更多领域展现出其价值和潜力。